I believe companies that have recently announced gigantic operational pivots into Coronavirus responses are good candidates for sale or short sale. One such company is Aytu BioSciences (AYTU), a very active Coronavirus announcer with a suspect historical product portfolio and a head-spinning capital structure.
On March 10, shares of Aytu rocketed from $0.35 to around $1.50 on the company’s announcement it had secured exclusive license to distribute a IgG/IgM Rapid Test for Coronavirus in the U.S. Amid an acceleration in fear about the pandemic, Aytu’s test captured investors’ imaginations with the promise of